ATR and cancer: To test this hypothesis, we designed an isogenic cellular model in HCT116 (CRC, MSI + cancer cell line), which showed that ATR mutation strongly sensitizes cells to SN-38 and VE-822 (ATR inhibitor), both alone and combined.